Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | CHIEF PORT. STRAT & ALNCE OFCR | January 29, 2024 | January 31, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUTRO BIOPHARMA, INC.
Report date January 29, 2024 · Filed January 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,279 |
Ending reported balance
After 2024-01-29 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-01-29 · Sale · Disposed 12,185 · Balance 12,803 F1: This transaction was entered into pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 29, 2023. Row 2 · 2024-01-29 · Exercise / conversion · Acquired 2,500 · Balance 15,303 Row 3 · 2024-01-29 · Tax withholding · Disposed 1,024 · Balance 14,279 F2: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2024-01-29 | Direct | 0 |
Reported balance
After 2024-01-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-29 · Exercise / conversion · Disposed 2,500 · Balance 0 F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was entered into pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 29, 2023.
F2: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F4: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 29, 2024 Filed Jan 31, 2024 16:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002065 · form4-01312024_090124.xml · derivative · entry 4 Vasquez Nicki · CIK 0001877585 · CHIEF PORT. STRAT & ALNCE OFCR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 1,024 | $4.99 | $5,109.76 |
DisclosureSEC source: 0001415889-24-002065 · form4-01312024_090124.xml · nonDerivative · entry 3 Vasquez Nicki · CIK 0001877585 · CHIEF PORT. STRAT & ALNCE OFCR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,279 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002065 · form4-01312024_090124.xml · nonDerivative · entry 2 Vasquez Nicki · CIK 0001877585 · CHIEF PORT. STRAT & ALNCE OFCR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 12,185 | $5.00 | $60,925.00 |
DisclosureSEC source: 0001415889-24-002065 · form4-01312024_090124.xml · nonDerivative · entry 1 Vasquez Nicki · CIK 0001877585 · CHIEF PORT. STRAT & ALNCE OFCR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,803 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 29, 2023. Read SEC document |
| July 12, 2023 Filed Jul 13, 2023 18:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042244 · doc4.xml · derivative · entry 3 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 3,250 shares Expires 2025-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on July 12, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| July 12, 2023 Filed Jul 13, 2023 18:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 1,123 | $4.70 | $5,278.10 |
DisclosureSEC source: 0001209191-23-042244 · doc4.xml · nonDerivative · entry 2 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,988 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| July 12, 2023 Filed Jul 13, 2023 18:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042244 · doc4.xml · nonDerivative · entry 1 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:46 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016794 · doc4.xml · derivative · entry 7 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 5,500 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:46 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016794 · doc4.xml · derivative · entry 6 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,250 Underlying: Common Stock · 6,750 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:46 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016794 · doc4.xml · derivative · entry 5 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-03-01 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:46 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 35,000 | $0.00 Strike: $5.79 | $0.00 |
DisclosureSEC source: 0001209191-23-016794 · doc4.xml · derivative · entry 4 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-02-28 F3 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 1, 2023, with 100% of the total shares vested and exercisable on March 1, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:46 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 4,990 | $5.79 | $28,892.10 |
DisclosureSEC source: 0001209191-23-016794 · doc4.xml · nonDerivative · entry 3 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,861 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:46 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016794 · doc4.xml · nonDerivative · entry 2 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:46 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 6,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016794 · doc4.xml · nonDerivative · entry 1 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005757 · doc4.xml · derivative · entry 3 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 1,019 | $7.50 | $7,642.50 |
DisclosureSEC source: 0001209191-23-005757 · doc4.xml · nonDerivative · entry 2 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,601 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005757 · doc4.xml · nonDerivative · entry 1 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2022 Filed Jul 13, 2022 18:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042072 · doc4.xml · derivative · entry 3 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,750 Underlying: Common Stock · 3,250 shares Expires 2025-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on July 12, 2022, subject to continued service through each vesting date. Read SEC document |
| July 12, 2022 Filed Jul 13, 2022 18:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 1,123 | $6.08 | $6,827.84 |
DisclosureSEC source: 0001209191-22-042072 · doc4.xml · nonDerivative · entry 2 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,120 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| July 12, 2022 Filed Jul 13, 2022 18:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042072 · doc4.xml · nonDerivative · entry 1 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016855 · doc4.xml · derivative · entry 5 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 5,500 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,253 | $8.17 | $18,407.01 |
DisclosureSEC source: 0001209191-22-016855 · doc4.xml · nonDerivative · entry 2 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,993 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016855 · doc4.xml · nonDerivative · entry 1 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 19:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016855 · doc4.xml · derivative · entry 4 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2026-03-04 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 19:23 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 36,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001209191-22-016855 · doc4.xml · derivative · entry 3 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2032-03-03 F3 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 4, 2022, with 100% of the total shares vested and exercisable on March 4, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 20:39 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006129 · doc4.xml · derivative · entry 3 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires 2025-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 20:39 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 1,024 | $10.39 | $10,639.36 |
DisclosureSEC source: 0001209191-22-006129 · doc4.xml · nonDerivative · entry 2 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,746 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 20:39 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006129 · doc4.xml · nonDerivative · entry 1 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2021 Filed Sep 28, 2021 18:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 3,906 | $18.62 | $72,724.25 |
DisclosureSEC source: 0001209191-21-057982 · doc4.xml · nonDerivative · entry 3 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,270 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.47 to $19.08 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 5,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057982 · doc4.xml · derivative · entry 4 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,969 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,063 | $19.23 | $39,671.49 |
DisclosureSEC source: 0001209191-21-057982 · doc4.xml · nonDerivative · entry 2 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,176 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 18:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 5,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057982 · doc4.xml · nonDerivative · entry 1 Vasquez Nicki · CIK 0001877585 · Chief Port. Strat & Alnce Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.